CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor

Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies

(2015) J. Remon et al.   CANCER TREATMENT REVIEWS

Tremelimumab for the treatment of malignant mesothelioma

(2015) Alice Guazzelli et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

(2015) Luana Calabrò et al.   Lancet Respiratory Medicine

Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?

(2014) Frank J Ward et al.   Immunotherapy

Acquisition of Suppressive Function by Activated Human CD4+CD25- T Cells Is Associated with the Expression of CTLA-4 Not FoxP3

(2014) Y. Zheng et al.   JOURNAL OF IMMUNOLOGY

Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles

(2014) Laura Esposito et al.   JOURNAL OF IMMUNOLOGY

The soluble isoform of CTLA-4 as a regulator of T-cell responses

(2013) Frank J. Ward et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

(2013) Stefania Laurent et al.   Journal of Translational Medicine

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

(2013) Luana Calabrò et al.   LANCET ONCOLOGY

Elevated circulating cytotoxic T lymphocyte-associated antigen-4 levels are related to lung function and inflammation in chronic obstructive pulmonary disease

(2013) Yongchun Shen et al.   RESPIROLOGY

CTLA-4 Expression and Polymorphisms in Lung Tissue of Patients with Diagnosed Non-Small-Cell Lung Cancer

(2013) Adam Antczak et al.   Biomed Research International

Basis of CTLA-4 function in regulatory and conventional CD4+ T cells

(2012) X. Tai et al.   BLOOD

Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer

(2012) Sandra Salvi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Soluble Form of CTLA-4 Is Present in Paediatric Patients with Acute Lymphoblastic Leukaemia and Correlates with CD1d+ Expression

(2012) Rita Simone et al.   PLoS One

Predicting survival in malignant mesothelioma

(2011) A. W. Musk et al.   EUROPEAN RESPIRATORY JOURNAL

Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B

(2011) Ju Cao et al.   MICROBIAL PATHOGENESIS

Circulating Soluble CTLA4 (sCTLA4) Is Elevated in Patients With Breast Cancer

(2010) Nasrollah Erfani et al.   CANCER INVESTIGATION

New Insights of CTLA-4 into Its Biological Function in Breast Cancer

(2010) H. Mao et al.   CURRENT CANCER DRUG TARGETS

A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury

(2009) R. Simone et al.   INTERNATIONAL IMMUNOLOGY

Cholesterol in pleural exudates depends mainly on increased capillary permeability

(2009) Luis Valdés et al.   Translational Research

CTLA-4 Is a Direct Target of Wnt/β-Catenin Signaling and Is Expressed in Human Melanoma Tumors

(2008) Kavita V. Shah et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Improved AIC selection strategy for survival analysis

(2007) Hua Liang et al.   COMPUTATIONAL STATISTICS & DATA ANALYSIS